Kurin Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced that third quarter revenues exceeded 150% over the same period in 2019. Kurin also reports that in the third quarter of 2020 sales have surpassed total revenues for 2019.
“Given the unprecedented times in which we find ourselves, we are pleasantly surprised to see a continuance of the strong demand that is fueling our rapid growth,” said Bob Rogers, CEO of Kurin, Inc. “Although the hospital world has changed, we’ve seen many hospitals implement Kurin during the pandemic, as they did not want to wait any longer to address their contaminated blood cultures. We have also seen an increase in the use of Kurin in many facilities underscoring the importance in the efficient use of resources and the fact that accuracy of tests has never been more important.”
Kurin’s revolutionary approach to the contaminated blood culture problem is elegantly simple, an intuitive design that requires no additional user steps. Kurin is a passive device that sidelines potential contaminants during blood culture collection—a method simply better than conventional diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and the life-threatening C. diff. infection.
About Kurin, Inc.
Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. Kurin, manufactured in San Diego, CA, has received FDA 510(k) market clearance. For more information about Kurin, visit the website at www.kurin.com.